Skip to main
RMD
RMD logo

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 21 analyst ratings
Hold
Strong Buy 10%
Buy 43%
Hold 33%
Sell 14%
Strong Sell 0%

Bulls say

ResMed has demonstrated significant operational efficiencies, with its gross margin increasing 230 basis points year-over-year to reach 59.2%, driven by improved pricing, manufacturing efficiencies, and lower component costs. Additionally, the company's respiratory sales in the Americas grew 12% to $749 million, showcasing resilience in a competitive market, while overall expectations for future patient growth remain strong, with 89% of healthcare practitioners anticipating an increase in CPAP patients. Despite potential slowdowns in revenue growth, the strategic shift towards improved product mix and digital health innovations positions ResMed favorably to enhance its operating margins further in the coming years.

Bears say

ResMed's financial outlook appears negative due to several key factors impacting its revenue and margins. The company is facing potential market share loss, particularly with competitors like Philips re-entering the flow generator market, coupled with headwinds from emerging GLP-1 weight loss drugs that may reduce treatment adherence among sleep apnea patients. Additionally, despite a recent organic revenue growth rate of 10% in F2Q25, the deceleration from the previous quarter's 11% raises concerns about future performance, particularly as margin pressures and a lowered earnings estimate for FY27 suggest challenges ahead.

ResMed (RMD) has been analyzed by 21 analysts, with a consensus rating of Hold. 10% of analysts recommend a Strong Buy, 43% recommend Buy, 33% suggest Holding, 14% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 21 analysts, ResMed (RMD) has a Hold consensus rating as of Jul 23, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $182.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $182.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.